• On 31 March 2026, Scholar Rock announced it had resubmitted its Biologics License Application to the FDA for apitegromab in spinal muscular atrophy, now incorporating both the Catalent Indiana site and a second U.S.-based fill-finish facility in line with recent regulatory guidance.
• The resubmission, coming after an earlier Complete Response Letter that cited only third-party manufacturing observations, highlights how Scholar Rock has worked with Novo Nordisk’s Catalent unit and the FDA to reinforce apitegromab’s supply chain and address prior process concerns without altering the underlying clinical package.
• We’ll now explore how this FDA-aligned resubmission, including the added fill-finish facility, reshapes Scholar Rock’s investment narrative around apitegromab.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Scholar Rock Holding Investment Narrative Recap

To own Scholar Rock, you need to be comfortable with a single lead asset, apitegromab, driving the story and the shift from pure R&D to potential commercialization. The resubmitted BLA is now the key near term catalyst, while regulatory and manufacturing timing across Catalent Indiana and the new fill finish partner remain the most important risks, given current losses of US$377.9 million in 2025 and no approved products yet.

Among recent developments, the March 3, 2026 Type C meeting with the FDA stands out, because it shaped the BLA resubmission strategy and the inclusion of a second U.S. fill finish facility. That interaction underpins the current apitegromab regulatory timeline in the U.S., sits alongside the ongoing EMA review in Europe, and frames how quickly Scholar Rock could move from absorbing heavy launch preparation costs to potentially generating product revenue.

Yet behind the cleaner regulatory path, investors should still be aware of the operational and financial strain if manufacturing or approval timelines slip...

Scholar Rock Holding's narrative projects $398.1 million revenue and $43.4 million earnings by 2029. This implies an earnings increase of about $421 million from -$377.9 million today.

Uncover how Scholar Rock Holding's forecasts yield a $55.07 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have two fair value estimates for Scholar Rock, clustered tightly between US$55.07 and US$57.21 per share. You can weigh those views against the central role of apitegromab’s regulatory progress, which could heavily influence when the company starts to offset its current losses with commercial revenue.

Explore 2 other fair value estimates on Scholar Rock Holding - why the stock might be worth as much as 16% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Scholar Rock Holding research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Scholar Rock Holding research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Scholar Rock Holding's overall financial health at a glance.

No Opportunity In Scholar Rock Holding?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 58 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.